See the Cosentyx dosing schedule and summary of product characteristics.
PsA and AS dosing: give your Cosentyx patients the ease of a monthly maintenance schedule1
Cosentyx, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.
*PsA patients initiated on 150 mg can be increased to 300 mg based on clinical response.
Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
For patients with active AS, the recommended dose is 150 mg by subcutaneous injection. AS patients initiated on 150 mg can be increased to 300 mg based on clinical response.
More product information
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
AS, ankylosing spondylitis; DMARD, disease-modifying anti-rheumatic drug; MTX, methotrexate; PsA, psoriatic arthritis; SC, subcutaneous; TNF, tumour necrosis factor-alpha.
- Cosentyx Summary of Product Characteristics.